A new vaccine against chikungunya is available, who can be affected?

As numerous cases of chikungunya are detected in France, a new preventive vaccine is available.

A second vaccine arrives at the right time. More than 1,500 cases of chikungunya—including two indigenous cases—have been detected in mainland France since the beginning of the year, especially since May, the start of the tiger mosquito's active period. Overseas, the epidemic is now "low intensity" in Réunion, but has been intensifying in Mayotte since the end of April. A new preventive vaccine was therefore expected in this context of active circulation of the virus in many places around the world.

Marketed by the Bavarian Nordic laboratory, the Vimkunya vaccine received marketing authorization in Europe in February 2025. However, for the time being, pending additional data from the laboratory, the French High Authority for Health (HAS) has not yet officially recommended it. This recombinant vaccine is already available by prescription, in pharmacies or at travel vaccination centers, but is not currently reimbursed. It is indicated for anyone 12 years of age and older.

The other vaccine already available, Ixchiq (Valneva), is currently recommended in areas where the virus is circulating - notably in Réunion - for 18-64 year olds, except for immunocompromised people. It was originally also available for those over 65, but several people in this age group have suffered serious adverse effects, and 3 deaths have even been associated with the vaccine. At present, "there is no vaccination recommendation from health authorities against chikungunya for travelers going to areas at risk of transmission," specifies the Ministry of Health .

The new Vimkunya vaccine thus meets a need among adolescents, those over 65, and vulnerable people who were unable to be vaccinated with the live attenuated Ixchiq vaccine. It could thus increase the population's protection against chikungunya in areas where there is an epidemic. Clinical trials of Vimkunya have shown an efficacy of 98% at 22 days after the injection, and 87% in those over 65. The immune response is maintained for at least 6 months, according tothe European Medicines Agency .